CZ20011521A3 - Farmaceutický prostředek obsahující fragmenty DNA kódující antigenní protein vykazující protinádorový účinek - Google Patents
Farmaceutický prostředek obsahující fragmenty DNA kódující antigenní protein vykazující protinádorový účinek Download PDFInfo
- Publication number
- CZ20011521A3 CZ20011521A3 CZ20011521A CZ20011521A CZ20011521A3 CZ 20011521 A3 CZ20011521 A3 CZ 20011521A3 CZ 20011521 A CZ20011521 A CZ 20011521A CZ 20011521 A CZ20011521 A CZ 20011521A CZ 20011521 A3 CZ20011521 A3 CZ 20011521A3
- Authority
- CZ
- Czechia
- Prior art keywords
- sequence
- fragment
- dna
- muc
- seq
- Prior art date
Links
- 239000012634 fragment Substances 0.000 title claims abstract description 103
- 108090000623 proteins and genes Proteins 0.000 title abstract description 23
- 102000004169 proteins and genes Human genes 0.000 title abstract description 21
- 230000000259 anti-tumor effect Effects 0.000 title abstract description 5
- 230000000890 antigenic effect Effects 0.000 title description 4
- 230000001747 exhibiting effect Effects 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 239000002671 adjuvant Substances 0.000 claims abstract description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 3
- 108020004414 DNA Proteins 0.000 claims description 118
- 239000013612 plasmid Substances 0.000 claims description 47
- 239000002773 nucleotide Substances 0.000 claims description 37
- 125000003729 nucleotide group Chemical group 0.000 claims description 37
- 239000013604 expression vector Substances 0.000 claims description 35
- 108010063954 Mucins Proteins 0.000 claims description 22
- 102000015728 Mucins Human genes 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 18
- 239000013598 vector Substances 0.000 claims description 16
- 238000010276 construction Methods 0.000 claims description 14
- 102000044159 Ubiquitin Human genes 0.000 claims description 12
- 108090000848 Ubiquitin Proteins 0.000 claims description 12
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 8
- 108090000695 Cytokines Proteins 0.000 claims description 6
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 241000588724 Escherichia coli Species 0.000 claims description 6
- 102100034256 Mucin-1 Human genes 0.000 claims description 6
- 244000005700 microbiome Species 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 4
- 102000053602 DNA Human genes 0.000 claims 2
- 108091026890 Coding region Proteins 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000013613 expression plasmid Substances 0.000 claims 1
- 230000028993 immune response Effects 0.000 abstract description 11
- 210000004881 tumor cell Anatomy 0.000 abstract description 11
- 108091034117 Oligonucleotide Proteins 0.000 description 34
- 150000001413 amino acids Chemical group 0.000 description 29
- 108020004707 nucleic acids Proteins 0.000 description 28
- 102000039446 nucleic acids Human genes 0.000 description 28
- 150000007523 nucleic acids Chemical class 0.000 description 28
- 108020004705 Codon Proteins 0.000 description 26
- 108090000765 processed proteins & peptides Proteins 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 21
- 102000004196 processed proteins & peptides Human genes 0.000 description 19
- 241000282414 Homo sapiens Species 0.000 description 15
- 206010028980 Neoplasm Diseases 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 15
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 14
- 238000013519 translation Methods 0.000 description 14
- 239000000427 antigen Substances 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- 229920001184 polypeptide Polymers 0.000 description 13
- 238000003757 reverse transcription PCR Methods 0.000 description 10
- 239000002299 complementary DNA Substances 0.000 description 8
- 230000001472 cytotoxic effect Effects 0.000 description 8
- 238000002255 vaccination Methods 0.000 description 8
- 231100000433 cytotoxic Toxicity 0.000 description 7
- 229960005486 vaccine Drugs 0.000 description 7
- 102100034343 Integrase Human genes 0.000 description 6
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 5
- 210000004443 dendritic cell Anatomy 0.000 description 5
- 229930182817 methionine Natural products 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 108091054437 MHC class I family Proteins 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108010008707 Mucin-1 Proteins 0.000 description 3
- 102000007298 Mucin-1 Human genes 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000005875 antibody response Effects 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 238000011238 DNA vaccination Methods 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 2
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 101100346929 Homo sapiens MUC1 gene Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 230000007402 cytotoxic response Effects 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 102000057860 human MUC1 Human genes 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- WALUVDCNGPQPOD-UHFFFAOYSA-M 2,3-di(tetradecoxy)propyl-(2-hydroxyethyl)-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCOCC(C[N+](C)(C)CCO)OCCCCCCCCCCCCCC WALUVDCNGPQPOD-UHFFFAOYSA-M 0.000 description 1
- OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 241000023308 Acca Species 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 230000003682 DNA packaging effect Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101710177504 Kit ligand Proteins 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 239000008051 TBE buffer Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 229940043263 traditional drug Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4727—Mucins, e.g. human intestinal mucin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT1998MI002330A IT1303683B1 (it) | 1998-10-30 | 1998-10-30 | Composizione farmaceutiche ad azione antitumorale contenente dnacodificante per frammenti di una proteina antigenica. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CZ20011521A3 true CZ20011521A3 (cs) | 2001-10-17 |
Family
ID=11380969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CZ20011521A CZ20011521A3 (cs) | 1998-10-30 | 1999-10-18 | Farmaceutický prostředek obsahující fragmenty DNA kódující antigenní protein vykazující protinádorový účinek |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1124956A2 (es) |
| JP (1) | JP2002528519A (es) |
| CN (1) | CN1324406A (es) |
| AR (1) | AR020927A1 (es) |
| AU (1) | AU1152200A (es) |
| BG (1) | BG105458A (es) |
| BR (1) | BR9914892A (es) |
| CA (1) | CA2348745A1 (es) |
| CO (1) | CO5231134A1 (es) |
| CZ (1) | CZ20011521A3 (es) |
| EA (1) | EA200100395A1 (es) |
| HU (1) | HUP0103784A2 (es) |
| IT (1) | IT1303683B1 (es) |
| MX (1) | MXPA01004186A (es) |
| PE (1) | PE20001287A1 (es) |
| PL (1) | PL348156A1 (es) |
| SK (1) | SK5712001A3 (es) |
| TR (1) | TR200101141T2 (es) |
| WO (1) | WO2000025827A2 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6548643B1 (en) | 1994-11-16 | 2003-04-15 | Austin Research Institute | Antigen carbohydrate compounds and their use in immunotherapy |
| EP1257565A4 (en) * | 2000-02-01 | 2005-04-06 | Austin Research Inst | DERIVED FROM MUCIN-1 ANTIGENE AND ITS USE IN IMMUNOTHERAPY |
| WO2002022685A2 (en) * | 2000-09-11 | 2002-03-21 | Kufe Donald W | Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom |
| JP4276432B2 (ja) | 2000-12-22 | 2009-06-10 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | Ｍｕｃ１による細胞増殖調節方法 |
| WO2004099389A2 (en) * | 2003-03-24 | 2004-11-18 | The Scripps Research Institute | Dna vaccines against tumor growth and methods of use thereof |
| US7696306B2 (en) | 2003-07-11 | 2010-04-13 | Board of Agents of the University of Nebraska | Compositions and methods for preventing or treating cancer |
| WO2005042573A1 (en) * | 2003-10-24 | 2005-05-12 | Dana-Farber Cancer Institute, Inc. | Modulation of the interaction of muc1 with muc1 ligands |
| WO2008097840A2 (en) | 2007-02-02 | 2008-08-14 | Dana-Farber Cancer Institute, Inc. | Methods and compositions relating to the regulation of muc1 by hsf1 and stat3 |
| WO2008097844A2 (en) | 2007-02-02 | 2008-08-14 | Dana -Farber Cancer Institute, Inc. | Methods and compositions relating to the regulation of apoptosis by muc1 and bh3- containing proapoptotic proteins |
| CN106279435B (zh) * | 2016-08-16 | 2019-06-07 | 新乡医学院 | 靶向VEGF与mucin1的抗肿瘤疫苗、编码基因、表达载体、表达工程菌及应用 |
| CN114230656A (zh) * | 2021-03-24 | 2022-03-25 | 深圳市新靶向生物科技有限公司 | 一种与食道癌驱动基因突变相关的抗原肽组合及其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1262545B (it) * | 1993-10-25 | 1996-07-02 | Menarini Ricerche Sud S P A A | Sistema di espressione per linee cellulari eucariotiche |
| CA2282300C (en) * | 1997-02-24 | 2011-08-02 | Therion Biologics Corporation | Recombinant pox virus for immunization against muc1 tumor-associated antigen |
-
1998
- 1998-10-30 IT IT1998MI002330A patent/IT1303683B1/it active
-
1999
- 1999-10-18 TR TR2001/01141T patent/TR200101141T2/xx unknown
- 1999-10-18 JP JP2000579265A patent/JP2002528519A/ja active Pending
- 1999-10-18 HU HU0103784A patent/HUP0103784A2/hu unknown
- 1999-10-18 WO PCT/EP1999/007874 patent/WO2000025827A2/en not_active Application Discontinuation
- 1999-10-18 CZ CZ20011521A patent/CZ20011521A3/cs unknown
- 1999-10-18 EP EP99971329A patent/EP1124956A2/en not_active Withdrawn
- 1999-10-18 AU AU11522/00A patent/AU1152200A/en not_active Abandoned
- 1999-10-18 MX MXPA01004186A patent/MXPA01004186A/es unknown
- 1999-10-18 CA CA002348745A patent/CA2348745A1/en not_active Abandoned
- 1999-10-18 CN CN99812745A patent/CN1324406A/zh active Pending
- 1999-10-18 BR BR9914892-7A patent/BR9914892A/pt not_active IP Right Cessation
- 1999-10-18 EA EA200100395A patent/EA200100395A1/ru unknown
- 1999-10-18 SK SK571-2001A patent/SK5712001A3/sk unknown
- 1999-10-18 PL PL99348156A patent/PL348156A1/xx unknown
- 1999-10-21 AR ARP990105316A patent/AR020927A1/es unknown
- 1999-10-22 PE PE1999001068A patent/PE20001287A1/es not_active Application Discontinuation
- 1999-10-29 CO CO99068636A patent/CO5231134A1/es not_active Application Discontinuation
-
2001
- 2001-04-20 BG BG105458A patent/BG105458A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2002528519A (ja) | 2002-09-03 |
| EA200100395A1 (ru) | 2001-10-22 |
| EP1124956A2 (en) | 2001-08-22 |
| CO5231134A1 (es) | 2002-12-27 |
| IT1303683B1 (it) | 2001-02-23 |
| BR9914892A (pt) | 2001-07-17 |
| BG105458A (en) | 2002-06-28 |
| HUP0103784A2 (hu) | 2002-02-28 |
| ITMI982330A1 (it) | 2000-04-30 |
| MXPA01004186A (es) | 2002-06-04 |
| ITMI982330A0 (it) | 1998-10-30 |
| PE20001287A1 (es) | 2000-12-07 |
| CN1324406A (zh) | 2001-11-28 |
| CA2348745A1 (en) | 2000-05-11 |
| SK5712001A3 (en) | 2002-04-04 |
| WO2000025827A3 (en) | 2000-08-10 |
| TR200101141T2 (tr) | 2001-09-21 |
| AU1152200A (en) | 2000-05-22 |
| PL348156A1 (en) | 2002-05-06 |
| WO2000025827A2 (en) | 2000-05-11 |
| AR020927A1 (es) | 2002-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7446185B2 (en) | Her2/neu target antigen and use of same to stimulate an immune response | |
| CN111533812B (zh) | 针对sars-cov-2病毒的dna疫苗及其用途 | |
| Schultz et al. | Long-lasting anti-metastatic efficiency of interleukin 12-encoding plasmid DNA | |
| KR20160106082A (ko) | Hpv 및 관련 질환용 면역 증강 치료 백신 | |
| JP2008528004A (ja) | 突然変異癌タンパク質抗原およびカルレティキュリンをコードするプラスミドを用いる抗癌ｄｎａワクチン | |
| WO2019101062A1 (zh) | 重组疫苗及其应用 | |
| EP4045081A1 (en) | Cancer vaccine | |
| CZ20011521A3 (cs) | Farmaceutický prostředek obsahující fragmenty DNA kódující antigenní protein vykazující protinádorový účinek | |
| JP2003517042A (ja) | 単純ヘルペスウイルスワクチンに対する免疫応答を強化する方法 | |
| EP1240317B1 (en) | Nucleic acid vaccination | |
| US20080095789A1 (en) | Vaccine | |
| US20060121010A1 (en) | Chorionic gonadotropin DNA vaccines and methods | |
| EP3986915A1 (en) | Recombinant interleukin 12 construct and uses thereof | |
| US20060062798A1 (en) | Vaccines | |
| JP2007505601A (ja) | ワクチン | |
| JP4459060B2 (ja) | ポリヌクレオチドからなるワクチン | |
| JPWO2003000894A1 (ja) | ポリヌクレオチドワクチン | |
| WO1998015285A9 (en) | Methods and compositions for inducing a protective immune response to cancers | |
| WO1998015285A1 (en) | Methods and compositions for inducing a protective immune response to cancers | |
| US20040198684A1 (en) | Vaccine comprising polynucleotides | |
| US20040132972A1 (en) | Tri-hybrid melanoma antigen | |
| CA3183774A1 (en) | Breast cancer vaccine | |
| Sfondrini | Enhancement of anti-tumour immunity by transduction with a Mycobacterium tuberculosis gene |